Natalizumab (Tysabri) in multiple sclerosis patients

Natalizumab (Tysabri) in multiple sclerosis patients

Authors

  • Viola Sacchi info@adreshe.com

DOI:

https://doi.org/10.7175/fe.v9i2.222

Abstract

Multiple sclerosis (MS) is an autoimmune disease where dysregulated immune system elements (i.e. leucocytes) react against different components of the central nervous system (CNS), in particular myelin structures, causing several physical and mental symptoms,
often progressing to total disability. While some treatments for MS provide only symptom relief, the most commonly drugs administered for altering the course of the disease are DMTs (disease-modifying therapies); nevertheless for more than ten years the only DMTs available were interferon β, glatiramer acetate (two immunomodulating drugs) and mitoxantrone (an immunosuppressant).

Downloads

Published

2008-06-15

How to Cite

Sacchi, V. (2008). Natalizumab (Tysabri) in multiple sclerosis patients. Farmeconomia. Health Economics and Therapeutic Pathways, 9(2), 109–114. https://doi.org/10.7175/fe.v9i2.222

Issue

Vol. 9 No. 2 (2008)

Section

Brief drug profile

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
  4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)